 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
18 December 2001 | Volume 135 Issue 12 | Pages 1047-1051
Background: Quinine-associated thrombotic thrombocytopenic purpura–hemolytic uremic syndrome (TTP–HUS) is thought to be uncommon and to have a good prognosis.
Objective: To describe the frequency, clinical features, and long-term outcomes of quinine-associated TTP–HUS.
Design: Case series.
Setting: Hospitals in central-western Oklahoma.
Patients: 225 consecutive patients with TTP–HUS, 1989-2000.
Measurements: Presenting features and clinical outcomes.
Results: Thrombotic thrombocytopenic purpura–hemolytic uremic syndrome was associated with quinine in 17 patients. Four patients died, and 7 survivors currently have chronic renal failure. Since 1 July 1995, 132 patients with clinically suspected TTP–HUS were explicitly asked about drug exposure. Fourteen (11%) had taken quinine, and 7 had taken other drugs associated with TTP–HUS. Neurologic abnormalities were as severe in patients with quinine-associated TTP–HUS as in the 118 patients who had not taken quinine.
Conclusions: Quinine is a common cause of drug-associated TTP–HUS and can cause death and chronic renal failure. When the disorder is described as TTP–HUS rather than only as HUS, the severity of neurologic abnormalities and the occasional absence of renal failure are emphasized. If recurrent disease is to be prevented, clinicians must recognize quinine as a possible cause.
Author and Article Information
From University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Acknowledgments: The authors thank Drs. George Dale (University of Oklahoma), Dania Yaskanin (Oklahoma Blood Institute), and Janice McFarland (Blood Center of Southeastern Wisconsin, Milwaukee) for performing the quinine-dependent antiplatelet antibody studies. They also thank the Patients' Services staff of the Oklahoma Blood Institute, the community physicians, and the patients for continuing support and participation.
Requests for Single Reprints: James N. George, MD, Hematology–Oncology Section, Department of Medicine, University of Oklahoma Health Sciences Center, Box 26901, Oklahoma City, OK 73190; e-mail, Jim-George{at}OUHSC.edu.
Current Author Addresses: Drs. Kojouri, Vesely, and George: Hematology–Oncology Section, Department of Medicine, University of Oklahoma Health Sciences Center, Box 26901, Oklahoma City, OK 73190.
Author Contributions: Conception and design: K. Kojouri, S.K. Vesely, J.N. George.
Analysis and interpretation of the data: K. Kojouri, S.K. Vesely, J.N. George.
Drafting of the article: K. Kojouri, S.K. Vesely, J.N. George.
Critical revision of the article for important intellectual content: K. Kojouri, S.K. Vesely, J.N. George.
Final approval of the article: K. Kojouri, S.K. Vesely, J.N. George.
Statistical expertise: K. Kojouri, S.K. Vesely, J.N. George.
Collection and assembly of data: K. Kojouri, S.K. Vesely, J.N. George. BRIEF COMMUNICATION
Quinine-Associated Thrombotic Thrombocytopenic Purpura–Hemolytic Uremic Syndrome: Frequency, Clinical Features, and Long-Term Outcomes
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  R. H. Aster and D. W. Bougie Drug-Induced Immune Thrombocytopenia N. Engl. J. Med., August 9, 2007; 357(6): 580 - 587. [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. George Evaluation and Management of Patients With Thrombotic Thrombocytopenic Purpura J Intensive Care Med, March 1, 2007; 22(2): 82 - 91. [Abstract] [PDF]
|
|
|
|
 |
|
 J. N. George Quinine: common remedy, serious reactions, new insights Blood, August 1, 2006; 108(3): 782 - 783. [Full Text] [PDF]
|
|
|
|
|
|
J. N. George Clinical practice. Thrombotic thrombocytopenic purpura. N. Engl. J. Med., May 4, 2006; 354(18): 1927 - 1935. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Fiaccadori, U. Maggiore, C. Rotelli, R. Giacosa, E. Parenti, A. Cabassi, K. Ariya, and L. Wirote Thrombotic-thrombocytopenic purpura following malaria prophylaxis with mefloquine J. Antimicrob. Chemother., January 1, 2006; 57(1): 160 - 161. [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Reddy, M. A. Shuman, and R. H. Aster Quinine/Quinidine-Induced Thrombocytopenia: A Great Imitator Arch Intern Med, January 26, 2004; 164(2): 218 - 220. [Full Text] [PDF]
|
|
|
|
|
|
S. K. Vesely, J. N. George, B. Lammle, J.-D. Studt, L. Alberio, M. A. El-Harake, and G. E. Raskob ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients Blood, July 1, 2003; 102(1): 60 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Olszewski and J. M. Shapiro Thrombotic Thrombocytopenic Purpura Associated with Abacavir in a Patient with HIV Infection J Intensive Care Med, May 1, 2003; 18(3): 156 - 159. [Abstract] [PDF]
|
|
|
|
|
|
T. G. DeLoughery Thrombocytopenia in Critical Care Patients J Intensive Care Med, November 1, 2002; 17(6): 267 - 282. [Abstract] [PDF]
|
|
|
|
|
|
J. L. Moake Thrombotic Microangiopathies N. Engl. J. Med., August 22, 2002; 347(8): 589 - 600. [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. George, J. E. Sadler, and B. Lammle Platelets: Thrombotic Thrombocytopenic Purpura Hematology, January 1, 2002; 2002(1): 315 - 334. [Abstract] [Full Text]
|
|
Article
